DrugPatentWatch Database Preview

Details for Patent: 7,947,017

Which drugs does patent 7,947,017 protect, and when does it expire?

Patent 7,947,017 protects AUVI-Q and EVZIO and is included in three NDAs.

This patent has one hundred patent family members in fourteen countries.

Summary for Patent: 7,947,017

Title:	Devices, systems and methods for medicament delivery
Abstract:	An apparatus includes a movable member and a valve coupled to the movable member. The movable member is configured to be disposed within a housing of a medical device and has a first end portion and second end portion. A portion of the first end portion is configured to define a portion of a boundary of a gas chamber. The first end portion defines an opening configured to be in fluid communication between the gas chamber and an area outside the gas chamber. The second end portion is configured to be coupled to a needle configured to deliver a medicament into a body. The valve is configured to selectively allow fluid communication between the gas chamber and the area outside the gas chamber through the opening defined by the first end portion of the movable member.
Inventor(s):	Edwards; Evan Thomas (Fredericksburg, VA), Edwards; Eric Shawn (Midlothian, VA), Licata; Mark J. (Doswell, VA)
Assignee:	Intelliject, Inc. (Richmond, VA)
Application Number:	11/566,422
Patent Claim Types: see list of patent claims	Composition; Device; Dosage form;

Drugs Protected by US Patent 7,947,017

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-003	Nov 17, 2017		RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-002	Aug 10, 2012	BX	RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-001	Aug 10, 2012	BX	RX	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Kaleo Inc	EVZIO	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	205787-001	Apr 3, 2014		DISCN	Yes	No	➤ Sign Up	➤ Sign Up	Y				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,947,017

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
7,648,483	Devices, systems and methods for medicament delivery	➤ Sign Up
7,731,686	Devices, systems and methods for medicament delivery	➤ Sign Up
8,361,029	Devices, systems and methods for medicament delivery	➤ Sign Up
7,731,690	Devices, systems and methods for medicament delivery	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 7,947,017

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004325202	➤ Sign Up
Australia	2006210865	➤ Sign Up
Australia	2007245139	➤ Sign Up
Australia	2009200841	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,947,017

For more information try a trial or see the plans and pricing